Emmanouel Magoulakis
Global Commercial Lead @Alnylam Pharmaceuticals
Signup · Get unlimited contacts
WORK HISTORY
Global Commercial Lead @Alnylam Pharmaceuticals
Cambridge, MA, US
Commercial lead for siRNA treatment for the Rare Disease of PH1 including market development, launch planning and partner with regional team and cross functional team.Revenue Growth: 17% YoY 2022, 57% YoY 2023, 52% YoY 2024.Report to VP and member of the leadership team. Commercial lead for siRNA treatment OXLUMO (lumasiran) for the rare disease of PH1, including new indication, life cycle planning, market development, launch planning, goal, partnering with regional and cross-functional teams and goal setting.• Strategy: Developed and executed global strategy and messaging in collaboration with cross-functional stakeholders.• Innovation: Artificial intelligence (AI) project to develop AI tool for localization, geotargeted banner ads, and HCP segmentation of marketing materials.• Business Planning: Led development of global operating plan, tactical plan, life-cycle management, and quarterly business review (QBR) for presentation to executive leadership team (ELT).• Global Launch Strategies: Messaged development, product positioning, TPP, segmentation, and go-to-market strategy and sequencing framework for expansion countries.• Market Research: Led competitive readiness strategy based on competitive profile, regional threat assessment, and segmentation drive insight into evolving treatment landscape through customer interactions and market research.• Stakeholder Leadership: Led global advisory boards, steering committees, and KOL engagements.• Brand Leadership: Developed and chaired medical, access, and commercial (MAC) forum to align program goals, KPIs, tactics, and messaging platform.
EDUCATION
University of Medicine and Dentistry of New Jersey
Master of Science - MS, Health Sciences
University of Cincinnati
BA
Fordham University
MBA
ABOUT EMMANOUEL MAGOULAKIS
Turning strategies into impact—that\'s been my journey over the past 15 years in the pharmaceutical and biotech worlds. I\'ve driven commercial marketing and sales across the US, regional, and global markets, launching 5 brands that make a real difference in oncology, hematology, and rare diseases. I have proven track record of delivering bottom line results in providing products to those patients in need. Demonstrated the ability to transcend cultural difference and thrive in a deadline environment.In an ever-evolving landscape, I stay ahead of the curve by leveraging the latest innovations in AI digital tools. I maximize reach and efficiency, ensuring that groundbreaking tools to raise awareness but also segmenting and targeting specific populations with action-oriented messaging. I have further leveraged AI to reduce costs with the ability to develop promotional material which can be easily adopted in every country reducing agency time, medical legal reviews and cost.• Driving Growth: I have over two decades of experience in the Oncology field and recently, three years in the Rare Disease space, achieving a 57% YoY growth in 2023 and a 40% YoY growth as of the end of Q3 2024.• Strategic Leadership: I bring comprehensive marketing experience across three disciplines: US, Regional (LATAM), and Global. In addition to field sales. I have led the Strategic vision through the development of the Global Brand Plan and which is adapted to each region and executed• Leadership in US & Global Launches: I have led successful 5 US and Global launches for Oncology therapeutics, including Accelerated Approvals under Subpart E&H.• KOL and Event Leadership: I have developed KOLs, led advisory boards and steering committees, and organized impactful speaker programs and symposiums outside the US.Disease Areas of Expertise:Oncology: Breast Cancer, Colorectal Cancer (CRC), Gastro Intestinal Stromal Tumor (GIST), Non-Small Cell Lung Cancer (NSCLC), Pancreatic Neuroendocrine Tumor (pNET), Renal Cell Carcinoma (RCC), Hematology: Chronic Myeloid Leukemia (CML), Immune Thrombocytopenia (ITP), Diffused Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL)Rare Disease / Nephrology: Primary Hyperoxaluria Type 1 (PH1)Contact: e••••••••@gmail.com
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.